OncoMatch/Clinical Trials/NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Is NCT07216105 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including FT836 and Paclitaxel for non-small cell lung cancer.
Treatment: FT836 · Paclitaxel · Cetuximab · Trastuzumab — This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
disease that has relapsed or progressed following at least one line of prior systemic therapy
Cannot have received: biological therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: chemotherapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: investigational therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: radiation therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Lab requirements
Blood counts
ANC >1000/µL without growth factor support within 7 days; Platelet count ≥75,000/µL without transfusion support within 14 days
Kidney function
Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
Liver function
Total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert syndrome); AST ≤3 × ULN or ALT ≤3 × ULN (≤5 × ULN with liver metastases); ALP ≤2.5 × ULN (≤5 × ULN with liver or bone metastases)
Cardiac function
Oxygen saturation >90% on room air
Evidence of adequate organ function as determined by all of the following: ANC >1000/µL without growth factor support within 7 days prior to start of first study intervention; Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention; Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method; Total bilirubin ≤1.5 × ULN; for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN; AST ≤3 × ULN or ALT ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN; ALP ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN; Oxygen saturation >90% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia, Pennsylvania
- M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify